- Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?
-
Kim SY
- KMID: 2504504
- Clin Mol Hepatol.
- 2020 Jul;26(3):309-311.
- doi: 10.3350/cmh.2020.0061
-
- CITED
-
- Close
- SHARE
-
- Close
- Macro-aspartate aminotransferase in a healthy woman
-
Lorubbio M, Ognibene A, Salvadori B, Fanelli A, Laffi G
- KMID: 2504513
- Clin Mol Hepatol.
- 2020 Jul;26(3):378-381.
- doi: 10.3350/cmh.2020.0069
-
- CITED
-
- Close
- SHARE
-
- Close
- Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
-
Han S, Kim DY
- KMID: 2504503
- Clin Mol Hepatol.
- 2020 Jul;26(3):305-308.
- doi: 10.3350/cmh.2020.0096
-
- CITED
-
- Close
- SHARE
-
- Close
- Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
-
Jang BK
- KMID: 2504505
- Clin Mol Hepatol.
- 2020 Jul;26(3):312-314.
- doi: 10.3350/cmh.2020.0099
-
- CITED
-
- Close
- SHARE
-
- Close
- How does low-level viremia affect the prognosis of patients with chronic hepatitis B?
-
Lee HW, Kim BK
- KMID: 2504512
- Clin Mol Hepatol.
- 2020 Jul;26(3):376-377.
- doi: 10.3350/cmh.2020.0121
-
- CITED
-
- Close
- SHARE
-
- Close
- Is liver biopsy still useful in the era of non-invasive tests?
-
Lim TS, Kim JK
- KMID: 2504502
- Clin Mol Hepatol.
- 2020 Jul;26(3):302-304.
- doi: 10.3350/cmh.2020.0081
-
- CITED
-
- Close
- SHARE
-
- Close
- Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?
-
Kim JH, Sinn DH
- KMID: 2504506
- Clin Mol Hepatol.
- 2020 Jul;26(3):315-317.
- doi: 10.3350/cmh.2020.0084
-
- CITED
-
- Close
- SHARE
-
- Close
- Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis
-
Thuy LTT, Hai H, Kawada N
- KMID: 2504500
- Clin Mol Hepatol.
- 2020 Jul;26(3):280-293.
- doi: 10.3350/cmh.2020.0037
Cytoglobin (Cygb), a stellate cell-specific globin, has recently drawn attention due to its association with liver fibrosis. In the livers of both humans and rodents, Cygb is expressed only in... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of liver diseases during the pandemic of coronavirus disease-19
-
Cho JY, Kim SS, Lee YS, Song DS, Lee JH, Kim JH, Korean Association for the Study of the Liver
- KMID: 2504497
- Clin Mol Hepatol.
- 2020 Jul;26(3):243-250.
- doi: 10.3350/cmh.2020.0111
-
- CITED
-
- Close
- SHARE
-
- Close
- Fecal microbiota transplantation in alcohol related liver diseases
-
Shasthry SM
- KMID: 2504501
- Clin Mol Hepatol.
- 2020 Jul;26(3):294-301.
- doi: 10.3350/cmh.2020.0057
The current standard of care for severe alcoholic hepatitis (SAH) has several limitations in that only up to one-third of patients are eligible for steroid therapy. Additionally, steroids have their... -
- CITED
-
- Close
- SHARE
-
- Close
- Novel biomarkers for the management of chronic hepatitis B
-
Inoue T, Tanaka Y
- KMID: 2504499
- Clin Mol Hepatol.
- 2020 Jul;26(3):261-279.
- doi: 10.3350/cmh.2020.0032
Hepatitis B virus (HBV) cannot be eliminated completely from infected hepatocytes because of the presence of intrahepatic covalently closed circular DNA (cccDNA). As chronic hepatitis B (CHB) can progress to... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years
-
Chang Y, Kim JI, Lee B, Kim SG, Jung MJ, Kim YS, Jeong SW, Jang JY, Yoo JJ
- KMID: 2504507
- Clin Mol Hepatol.
- 2020 Jul;26(3):318-327.
- doi: 10.3350/cmh.2019.0019n
Background/Aims: Liver biopsy (LB) remains the gold standard for the evaluation of liver disease. However, over the past two decades, many noninvasive tests have been developed and utilized in clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
-
Huang CF, Yu ML
- KMID: 2504498
- Clin Mol Hepatol.
- 2020 Jul;26(3):251-260.
- doi: 10.3350/cmh.2020.0018
The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can be provided by novel... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
-
Lee CH, Lee YB, Kim MA, Jang H, Oh H, Kim SW, Cho EJ, Lee KH, Lee JH, Yu SJ, Yoon JH, Kim TY, Kim YJ
- KMID: 2504508
- Clin Mol Hepatol.
- 2020 Jul;26(3):328-339.
- doi: 10.3350/cmh.2019.0049n
Background/Aims: Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir
-
Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang SJ, Shin JW, Park BR, Park EJ, Park NH
- KMID: 2504511
- Clin Mol Hepatol.
- 2020 Jul;26(3):364-375.
- doi: 10.3350/cmh.2020.0012
Background/Aims: Low-level viremia (LLV) after nucleos(t)ide analog treatment was presented as a possible cause of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). However, detailed information on patients’... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging
-
Lee S, Kim Ss, Chang Dr, Kim H, Kim MJ
- KMID: 2504509
- Clin Mol Hepatol.
- 2020 Jul;26(3):340-351.
- doi: 10.3350/cmh.2020.0004
Background/Aims: This study aimed to compare the diagnostic performances of Liver Imaging Reporting and Data System (LI-RADS) 2018 and Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) 2018 criteria on magnetic... -
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
-
Woo HY, Park JY, Bae SH, Kim CW, Jang JY, Tak WY, Kim DJ, Kim IH, Heo J, Ahn SH
- KMID: 2504510
- Clin Mol Hepatol.
- 2020 Jul;26(3):352-363.
- doi: 10.3350/cmh.2019.0044n
Background/Aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus... -
- CITED
-
- Close
- SHARE
-
- Close
